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Introduction: Obesity is associated with a higher risk of abortion in women undergoing
in vitro fertilization (IVF). Whether thrombophilia amplifies this risk is currently unclear. The
aim of this study was to evaluate the effects of thrombophilia on the risk of abortion in
obese women treated with IVF.
Methods: Patient characteristics, presence of inherited or acquired thrombophilia, and
comorbidities were prospectively collected before the procedure in consecutive women
undergoing IVF. The primary outcome was the incidence of abortion among women who
achieved a clinical pregnancy.
Results: A total of 633 non-obese and 49 obese Caucasian women undergoing IVF were
included. 204 (32%) women achieved clinical pregnancy, of whom six had an ectopic
pregnancy and 63 experienced an abortion. The incidence of abortion was higher in obese
women compared to non-obese women after adjusting for age (64.3% vs. 29.3%, odds
ratio [OR] 4.41; 95% CI 1.41 to 13.81). Women with one or more thrombophilia were at
increased risk of abortion relative to those without thrombophilia (OR 2.70; 95% CI 1.34 to
5.45), and the risk seemed to be higher with hereditary (OR 5.12; 95% CI 1.77 to 14.8) than
acquired thrombophilia (OR 1.92; 95% CI 0.52 to 5.12; p for interaction 0.194). Among
obese women, the presence of one or more thrombophilia seemed associated with a
substantially increased risk of abortion (unadjusted OR 14.00; 95% CI 0.94 to 207.6).
Conclusions: Obese women undergoing IVF have a high risk of abortion which seems
further amplified by the concomitant presence of thrombophilia.
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The overall number of assisted reproductive technology (ART)
procedures has constantly grown during the last decades,
however, the average proportion of successful attempts
remains relatively low (1). The reasons behind the high rates of
implantation and placentation failure remain largely unknown.
High body mass index (BMI) is one of the most extensively
investigated risk factors which may have a negative impact on
fertility treatment outcomes (2). Several cohort studies
consistently reported an increased risk of abortion in obese
women undergoing in vitro fertilization (IVF) compared to
normal weight women. In a recent meta-analysis evaluating the
correlation between high BMI and ART outcomes, women with
BMI >30 kg/m2 had 20% lower live birth rate and 50% higher
miscarriage rate relative to women with normal BMI (2). The
low-grade chronic inflammation and hypercoagulability state
that are associated with obesity may increase the risk of
thrombotic complications and have negative effects on
reproduction (3–5). The procoagulant state could result in the
thrombotic occlusion of maternal vessels leading to impaired
intervillous space perfusion and placentation failure.
In principle, the presence of thrombophilia could amplify the
pro-thrombotic tendency of obese women and the risk of IVF
failure. Thrombophilia is a heritable or acquired abnormality of
blood coagulation that increases the risk of thrombosis. Both
inherited and acquired thrombophilia have been associated with
recurrent pregnancy loss and pregnancy complications, and
preliminary evidence suggested that thrombophilia may increase
the risk of IVF failure, although data remain conflicting (6–8).
The aims of this study were to assess IVF outcomes in obese
women compared to non-obese women, and evaluate whether
the risk of abortion and IVF failure may be increased by the
presence of concomitant thrombophilia.MATERIALS AND METHODS
Study Population
The main characteristics of the study population have been
described previously (7, 9). Briefly, consecutive women <40 years
who were scheduled for IVF at our University Center of
Reproductive Medicine, Ortona General Hospital, Chieti, Italy
from March 2015 to July 2017 were eligible. Exclusion criteria
were ongoing anticoagulation or indication for anticoagulant
treatment, embryo transfer not performed, and ovarian hyper-
stimulation syndrome. In addition, women who did not undergo
any of the routine screening for thrombophilia were excluded. At
the initial study visit before IVF, we collected information on
demographics, comorbidities, personal obstetric history, cause of
infertility, prior IVF attempts, thrombophilia screening results, and
concomitant medications.
Patients underwent controlled ovarian stimulation and
follicle growth monitoring. Ovum pick-up was scheduled 36 h
after recombinant human chorionic gonadotropin injection. The
embryo transfer was performed under ultrasound abdominalFrontiers in Endocrinology | www.frontiersin.org 2guidance about 72–76 h after ovum pick-up. In accordance with
national guidelines, a maximum of three embryos were
transferred in uterus. The luteal phase was supported with
daily intramuscular injections of progesterone 100 mg
(Prontogest, IBSA, Italy) from the day of ovum pick-up until
the beta human chorionic gonadotropin serum test was
performed at 14th day after the embryo transfer. All IVF
procedures were performed by intracytoplasmic sperm
injections, and each woman was included only once in the
study. A biochemical pregnancy was diagnosed in case of
detection of beta human chorionic gonadotropin in serum or
urine. Clinical pregnancy was defined as the presence of one or
more intrauterine sacs, and the clinical pregnancy rate
represented the proportion of women with a clinical pregnancy
on the total number of patients who underwent embryo transfer.
The live birth rate was defined as the number of deliveries
resulting in at least one alive baby out of the number of all
patients who underwent embryo transfer.
Blood samples were collected in 3.8% trisodium citrate tubes and
centrifuged at 4,000 g for 15min to obtain platelet-poor plasma. The
thrombophilia panel that was routinely requested included
hereditary thrombophilia such as factor V Leiden, prothrombin
G20210A mutation, deficiency of protein C, protein S, or
antithrombin, and acquired thrombophilia including lupus
anticoagulant, and anti-cardiolipin and anti-beta2 glycoprotein
antibodies. Thresholds for positivity are described in our previous
reports (7, 9). The study was approved by the local institutional
review board, and all women signed a written informed consent
before study procedures.
Outcomes
The main outcome of the study was spontaneous abortion (or
miscarriage), defined as intrauterine pregnancy demise
confirmed by ultrasound or histology (10). Early abortion was
defined as spontaneous pregnancy termination prior to 10 weeks’
gestation (10). The occurrence of abortion was evaluated in all
women who achieved a clinical pregnancy, except those with an
ectopic pregnancy.
The secondary outcome was IVF failure, which was defined as
a failure to conceive a child among all patients who underwent
embryo transfer.
Statistical Analysis
In the descriptive analyses, continuous variables are presented as
means (standard deviation), and categorical variables as numbers
(percentage). Differences in baseline characteristics between
obese women and non-obese women were tested with the
Mann-Whitney and Chi-squared test, as appropriate. BMI was
calculated in kg/m2 from patients’ height and weight, and used to
classify women into two categories: non-obese women with BMI
<30 kg/m2 and obese women with BMI ≥30 kg/m2. The
association with abortion and IVF failure was first described
with unadjusted odds ratios (OR) and corresponding 95%
confidence intervals (95% CI). We performed exploratory
analysis with multivariable logistic regression using two
different models: Model 1 used binary predictor variables forDecember 2020 | Volume 11 | Article 594867
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or more thrombophilia versus none) adjusting each of them for
age as a continuous variable, and Model 2 that included both
binary variables, age as a continuous variable, and an interaction
term to determine if the effects of thrombophilia differed by
obesity status. In secondary analysis, the risks of abortion and
IVF failure were evaluated in patients with hereditary versus
acquired thrombophilia. Wald test P values were reported for the
effects of obesity, thrombophilia and age. Survival curves for
abortion were calculated using the Kaplan‐Meier method with
patients right censored at the time of delivery. A p-value of 0.05
(two tailed) was considered significant. All analyses were
performed with RStudio, Version 1.1.423 – © 2009-2018
RStudio, Inc.Frontiers in Endocrinology | www.frontiersin.org 3RESULTS
Out of 687 women undergoing IVF, five were excluded because
BMI was not available (n=3) or patient was lost to follow-up
(n=2). A total of 682 women were considered in the final
analysis, including 633 (92.8%) non-obese and 49 (7.2%) obese
women. In this latter group, 37 (76%) women had mild obesity
(BMI between 30 kg/m2 and 35 kg/m2), 10 (20%) had moderate
obesity (BMI between 35 kg/m2 and 40 kg/m2), and 2 (4%) had
severe obesity (BMI above 40 kg/m2) (11).
The baseline characteristics of the study population are
reported in Table 1. Mean age was 34.6 years ( ± 3.26) and
mean BMI was 22.9 kg/m2 ( ± 4.15). Age, IVF indication,
previous pregnancies and IVF cycles, and the number ofTABLE 1 | Baseline characteristics of study population.
Overall Obese women Non-obese women p-value
N = 682 N = 49 N = 633
Age, years 34.6 (3.26) 34.8 (3.6) 34.6 (3.2) 0.643
BMI, kg/m2
Smoking 0.266
Current 98 (14.4) 5 (10.2) 93 (14.7)
Previous 11 (1.6) 2 (4.1) 9 (1.4)
Hypertension 5 (0.7) 2 (4.1) 3 (0.5) 0.047
Diabetes 1 (0.1) 1 (2.0) – 0.097
Aspirin 6 (0.9) – 6 (0.9) 1
IVF indication 0.088
Ovulatory 59 (8.7) 4 (8.2) 55 (8.7)
Tubaric 150 (22.0) 8 (16.3) 142 (22.4)
Endometriosis 55 (8.1) – 55 (8.7)
Male 196 (28.7) 15 (30.6) 181 (28.6)
Idiopathic 144 (21.1) 11 (22.4) 133 (21.0)
Mixed 61 (8.9) 9 (18.4) 52 (8.2)
Uterine 12 (1.8) 2 (4.1) 10 (1.6)
Multiple abortion 5 (0.7) – 5 (0.8)
Previous IVF cycles 0.208
0 415 (60.9) 34 (69.4) 381 (60.2)
1 150 (22.0) 12 (24.5) 138 (21.8)
≥ 2 115 (16.9) 3 (6.1) 112 (17.7)
Previous pregnancy
Ectopic 35 (5.1) 2 (4.1) 33 (5.2) 0.905
Spontaneous 60 (8.8) 3 (6.1) 57 (9.0) 0.728
Following ICSI 60 (8.8) 4 (8.2) 56 (8.8) 0.912
Previous abortion
Before 12 weeks 31 (4.5) 5 (10.2) 26 (4.1) 0.124
After 12 weeks 6 (0.9) – 6 (0.9) 0.649
Follicle stimulating hormone, IU/mL 8.01 (4.11) 7.60 (3.88) 8.04 (4.13) 0.472
bhCG*, mIU/mL 2818.61 (1401.14) 3095.59 (1390.27) 2797.10 (1,400.78) 0.151
Number of transferred grade A embryos 0.6
0 36 (5.3) 2 (4.1) 34 (5.4)
1 94 (13.8) 9 (18.4) 85 (13.4)
≥ 2 552 (80.9) 38 (77.6) 514 (81.2)
Number of transferred grade B embryos 0.697
0 505 (74.0) 35 (71.4) 470 (74.2)
1 128 (18.8) 9 (18.4) 119 (18.8)
≥ 2 49 (7.2) 5 (10.2) 44 (7.0)
Number of transferred grade C embryos 0.086
0 666 (97.7) 48 (98.0) 618 (97.6)
1 12 (1.8) – 12 (1.9)
≥ 2 2 (0.3) – 2 (0.3)
Thrombophilia* 141 (20.7) 18 (36.7) 123 (19.4) 0.007December 2020 | Volume 11 | ArticleValues are reported as mean ( ± SD) and numbers (%).
IVF, in vitro fertilization; ICSI, intra-cytoplasmic sperm injection; bhCG, beta human chorionic gonadotropin; *details on thrombophilia type are provided in the Supplementary Table.594867
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women (Table 1).
Overall, 227 (33%) women obtained a biochemical
pregnancy, of whom 204 achieved a clinical pregnancy
resulting in a clinical pregnancy rate of 29.9%. Eventually, 138
women delivered at least one live baby corresponding to a live
birth rate of 20.2%. The proportion of biochemical pregnancy,
clinical pregnancy, and live birth rate were comparable between
obese and non-obese women (Table 2). Six out of 204 women
with a clinical pregnancy had an ectopic pregnancy (5 in non-
obese women and 1 in obese women, p = 0.913). 63 (32%) of the
remaining 198 women experienced an abortion, of whom 54
(29.3%) were non-obese, and nine (64.3%) obese (p = 0.016)
(Figure 1). Abortion occurred early in eight (57.1%) obese
women and in 38 (20.7%) non-obese women.
Obesity and In Vitro
Fertilization Outcomes
The risk of abortion was substantially increased in obese women
compared to non-obese women (unadjusted OR 4.33; 95% CI
1.39 to 13.53), with an association that remained significant after
adjusting for age (OR 4.41; 95% CI 1.41 to 13.81; p = 0.011). The
effect of age was negligible (OR 1.03; 95% CI 0.93 to 1.13; p =
0.556). 54.5% of women with mild obesity had an abortion
compared to 100% of women with moderate obesity, whereas
none of the women with severe obesity achieved a clinical
pregnancy. A total of 544 (79.8%) patients had IVF failure,
which appeared to be higher in obese than non-obese women,
although the association was not statistically significant
(unadjusted OR 1.89; 95% CI 0.79 to 4.53). This risk remained
similar after adjusting for age (OR 1.88; 95% CI 1.88 0.78 to 4.51;
p = 0.16). There was a trend for a small effect of age on IVF
failure with 5% increase in risk for each year of age (OR 1.05;
95% CI 1.10 to 1.11; p = 0.074).Frontiers in Endocrinology | www.frontiersin.org 4Thrombophilia and In Vitro
Fertilization Outcomes
Overall, 141 (20.7%) women had at least one thrombophilia
consisting in one thrombophilic defect in 121 (17.7%) women,
two thrombophilic defects in 17 (2.5%), and three or more
thrombophilic defects in three (0.4%) women.
The prevalence of individual thrombophilia ranged from
0.1% to 4.5% with the least represented thrombophilia being
factor V Leiden homozygosity which was found in only 1 (0.1%)
patient (Supplementary Table). Eighteen (36.7%) obese women
had one or more thrombophilia compared to 123 (19.4%) non-
obese women (p = 0.007). The frequency of individual
thrombophilia in the overall study population, obese and non-
obese patients is provided in the Supplementary Table. In
univariable analysis, thrombophilia was associated with an
increased risk of abortion (OR 2.71; 95% CI 1.35 to 5.47), and
a not statistically higher risk of IVF failure (OR 1.48; 95% CI 0.90TABLE 2 | In vitro fertilization (IVF) outcomes according to the presence of obesity and thrombophilia.
Overall Obese women Non-obese women p-value* No thrombophilia ≥ 1 thrombophilia p-value*
N = 682 N = 49 N = 633 N = 541 N = 141
Biochemical pregnancy 227 (33.3) 18 (36.7) 209 (33.0) 0.708 180 (33.3) 47 (33.3) 1
Clinical pregnancy 204 (29.9) 15 (30.6) 189 (29.9) 1 160 (29.6) 44 (31.2) 0.785
Singleton 162 (23.8) 13 (26.5) 149 (23.5) 125 (23.1) 37 (26.2)
Twin 35 (5.1) 2 (4.1) 33 (5.2) 28 (5.2) 7 (5.0)
Triplet 7 (1.0) – 7 (1.1) 7 (1.3) 0 (0.0)
Ectopic pregnancy 6 (0.9) 1 (2.0) 5 (0.8) 0.913 4 (0.7) 2 (1.4)
Abortion* 63 (9.2) 9/14 (64.3) 54/184 (29.3) 0.016 42/160 (26.2) 21/44 (47.7) 0.011
Delivery type 0.383 0.055
Vaginal 52 (7.6) 1 (2.0) 51 (8.1) 43 (7.9) 9 (6.4)
Cesarean 89 (13.0) 5 (10.2) 84 (13.3) 77 (14.2) 12 (8.5)
Deliveries 0.485 0.33
Singleton 108 (15.8) 5 (10.2) 103 (16.3) 91 (16.8) 17 (12.1)
Twin 29 (4.3) 1 (2.0) 28 (4.4) 24 (4.4) 5 (3.5)
Triplet 4 (0.6) – 4 (0.6) 4 (0.7) –
Live birth 141 (71.2) 6 (12.2) 135 (21.3) 0.184 119 (22.0) 22 (15.6) 0.12
IVF failure 544 (79.8) 43 (87.8) 501 (79.1) 0.208 425 (78.6) 119 (84.4) 0.156December 2020 | Volume 11 | ArticlValues are reported as numbers (%).
*Abortion was evaluated in women with clinical pregnancy, after excluding women with an ectopic pregnancy. P-values were calculated with Mann-Whitney test for continuous variables
and with Chi-squared test for categorical variables.FIGURE 1 | Risk of abortion in non-obese and obese patients according to
the presence of thrombophilia.e 594867
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age (OR for abortion 2.70; 95% CI 1.34 to 5.45; p = 0.005, and OR
for IVF failure 1.47; 95% CI 0.89 to 2.43; p = 0.119). The effect of
age was estimated with an OR of 1.05 (95% CI 1.00 to 1.11; p =
0.074) for abortion and OR 1.05 (95% CI 1.00 to 1.11; p = 0.073)
for IVF failure.
Compared to patients without thrombophilia, women with
hereditary thrombophilia had a fivefold higher risk of abortion
after adjusting for age (OR 5.12; 95% CI 1.77 to 14.8; p = 0.003).
The risk seemed increased also in women with acquired
thrombophilia, but the difference did not reach statistical
significance (OR 1.92; 95% CI 0.52 to 5.12; p = 0.194).
Obesity and Concomitant Thrombophilia
Obese women with one or more thrombophilia seemed to have a
substantially higher risk of abortion compared to obese women
without thrombophilia (unadjusted OR 14.00; 95% CI 0.94 to
207.6), non-obese patients with (unadjusted OR 10.00; 95% CI
1.10 to 90.59) or without thrombophilia (unadjusted OR 19.25;
95% CI 2.30 to 161.39).
As shown in Figure 2, abortion occurred during the first 10
weeks of gestation in 75.0% of obese women with one or more
thrombophilia, in 33.3% of obese women without thrombophilia,
and in 20.7% of non-obese women.
Model 2 suggested a higher risk of abortion in the presence of
obesity and thrombophilia, although the interaction term was
not statistically significant (OR 7.46; 95% CI 0.45 to 125.91).
Obese patients with one or more thrombophilia seemed to
have an increased risk of IVF failure compared to obese patients
without thrombophilia (unadjusted OR 3.27; 95% CI 0.35 to
30.47), non-obese patients with one or more thrombophilia
(unadjusted OR 3.50; 95% CI 0.44 to 27.76), and non-obese
patients without thrombophilia (unadjusted OR 4.73; 95% CI
0.62 to 35.93), although none of these effects reached statisticalFrontiers in Endocrinology | www.frontiersin.org 5significance. The interaction term of obesity and thrombophilia
in Model 2 was estimated to be 2.81, but the confidence interval
was wide including the value of no effect (95% CI 0.28 to 28.06).DISCUSSION
The results of the present study showed that obesity and
thrombophilia are both associated with a high risk of abortion
in women undergoing IVF. The risk seemed to be substantially
increased by the concomitant presence of thrombophilia and
obesity, and seemed to be particularly high during the first 10
weeks of gestation.
The association between obesity and risk of abortion is
consistent with previous observations and the findings of a
recent meta-analysis on the correlation between BMI and ART
outcomes, which showed that women with BMI ≥ 30 kg/m2 had
50% higher risk of miscarriage compared to those with normal
BMI. (2) Other studies did not observe a significant relationship
between obesity and abortion or reported a lower risk in patients
with elevated BMI (12, 13). The discrepant findings may be
attributable to differences in study population, procedures,
outcome definition, and type of statistical analyses (12, 13). In
an earlier retrospective cohort by Zhang and colleagues, the
abortion rate was not statistically different between obese,
overweight, and normal weight women (11.1%, 13.6%, 8.4%
respectively; p > 0.05) (13). Interestingly, only 1% of 2,628
patients included in that study were obese, which is
significantly lower compared to the proportion of obese
women evaluated in the current and previous cohorts (2).
Our findings extend earlier observations suggesting that the
risk of abortion is amplified in obese women who have
concomitant thrombophilia. Obesity and thrombophilia may
have synergistic effects and activate blood coagulation beyondFIGURE 2 | Kaplan-Meyer curves for abortion.December 2020 | Volume 11 | Article 594867
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pregnancy, potentially increasing the risk of placental vessels
thrombosis, pregnancy loss, and pregnancy complications (6–8,
14). Our analysis is limited by the relative low number of obese
women included, which resulted in wide confidence intervals
around the effects of thrombophilia in these patients. If
confirmed, our data may have implications for the counselling
of obese women seeking IVF treatment. Thrombophilia testing
could be considered in these patients to inform them about the
effects of increased BMI and concomitant thrombophilia on IVF
outcomes and increased risk of early abortion. While speculative,
these findings support the hypothesis that antithrombotic
treatment may improve IVF outcomes in obese patients with
thrombophilia. Preliminary data suggested that the administration
of low-molecular-weight heparin is associated with higher clinical
pregnancy and live birth rates in women undergoing IVF or
intracytoplasmic sperm injection. (14). The use of heparin
would be an attractive treatment option in obese women
undergoing IVF, who seem to derive less benefit from weight
loss compared to obese women conceiving spontaneously (15).
The efficacy and safety of antithrombotic therapy has not been
evaluated specifically in obese women undergoing IVF, and
adequately powered randomized studies are warranted before
considering heparin treatment in these patients.
Our study has some limitations that need to be discussed. The
number of obese women was relatively low reducing the overall
power of the analysis and hampering the model fit in Model 2,
thus all estimations should be interpreted cautiously. The low
number of obese women precluded the evaluation of the
relationship between individual thrombophilia and IVF
outcomes. About half of patients lacked evaluation of all
thrombophilia, possibly affecting the strength of the
associations. Therefore, the apparent higher risk of abortion in
women with hereditary thrombophilia may be a spurious effect
and requires additional investigation. The incomplete assessment
was most often related to the patient’s decision to proceed to IVF
avoiding further delays and costs associated with laboratory
testing, which also highlights possible challenges for
implementing thrombophilia testing in clinical practice.
In conclusion, obesity and thrombophilia were both
independently associated with a significantly higher risk of
abortion in women undergoing IVF. The presence of concomitantFrontiers in Endocrinology | www.frontiersin.org 6thrombophilia and obesity seemed to amplify this risk substantially.
If confirmed, these findings may be useful for risk stratification,
patient counselling, improvement of prevention strategies, as well as
for designing future interventional studies.DATA AVAILABILITY STATEMENT
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